Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexusFeng-Ming Spring Kong, Timothy Ritter, Douglas J Quint, et al.JAMA Oncology|June 2, 2017
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical TrialFeng-Ming Kong, Randall K Ten Haken, Matthew Schipper, et al.Clinical and Translational Gastroenterology|December 22, 2023
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis RegistryHans H Herfarth, Anita Afzali, Monika Fischer, et al.Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.Inflammatory Bowel Diseases|June 14, 2022
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world SettingMillie D Long, Anita Afzali, Monika Fischer, et al.Annals of the Rheumatic Diseases|May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.Current Oncology (Toronto, Ont.)|August 28, 2024
Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT ExperienceAbhishek A Solanki, Kevin Zheng, Alicia N Skipworth, et al.Pageof 5